Goldman Sachs Boosts Quest Diagnostics Price Target to $78.00 (DGX)
Investment analysts at Goldman Sachs hoisted their price objective on shares of Quest Diagnostics (NYSE:DGX) from $66.00 to $78.00 in a note issued to investors on Wednesday. Goldman Sachs’ target price suggests a potential upside of 23.63% from the stock’s previous close.
DGX has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Friday, August 1st. They now have a $64.00 price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Friday, July 25th. They now have a $65.00 price target on the stock, up previously from $60.00. Finally, analysts at Maxim Group raised their price target on shares of Quest Diagnostics from $68.00 to $74.00 in a research note on Friday, July 25th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $62.46.
Quest Diagnostics (NYSE:DGX) opened at 63.09 on Wednesday. Quest Diagnostics has a 1-year low of $50.46 and a 1-year high of $64.10. The stock’s 50-day moving average is $61.56 and its 200-day moving average is $58.43. The company has a market cap of $9.111 billion and a P/E ratio of 11.88.
Quest Diagnostics (NYSE:DGX) last released its earnings data on Thursday, July 24th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.02. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter in the previous year, the company posted $1.06 earnings per share. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. On average, analysts predict that Quest Diagnostics will post $4.05 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Wednesday, October 22nd. Stockholders of record on Tuesday, October 7th will be given a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a yield of 2.09%. The ex-dividend date of this dividend is Friday, October 3rd.
Quest Diagnostics Incorporated (NYSE:DGX) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.